Dilated Cardiomyopathy (DCM) Market Insights 2030
Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle
that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or
restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers
become stretched, thickened or stiff; this affects the heart's ability to pump blood
around the body.
DelveInsight’s ‘Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology
and Market Forecast —2030’ report delivers an in-depth understanding of the
Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated
Cardiomyopathy market trends in the United States, EU5 (Germany, France, Italy,
Spain, and United Kingdom), and Japan.
The Dilated Cardiomyopathy market report provides current treatment practices,
emerging drugs, Dilated Cardiomyopathy market share of the individual therapies,
current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030
segmented by seven major markets.
Dilated Cardiomyopathy Overview
Dilated Cardiomyopathy (DCM) is characterized by left ventricular or biventricular
dilation and impaired contraction, which lessens the heart effectiveness at pumping
blood that is not explained by abnormal loading conditions like hypertension, valvular
heart disease or coronary artery disease. It is a non-ischemic heart muscle disease
with structural and functional myocardial abnormalities.
The World Health Organization (WHO) defines DCM as a severe cardiac disorder in
which structural or functional abnormalities of the heart muscle can lead to substantial
morbidity and mortality owing to complications such as heart failure and arrhythmia.
Dilated Cardiomyopathy Diagnosis
The diagnosis of DCM is mainly based on the person's symptoms, the results of a
physical examination, and